Oncology

Top news of the day from across the health care landscape.

Biovica’s DiviTum assay offers noninvasive tool to monitor efficacy of CDK4/6 inhibitors.

German shepherds undergo training to detect breast cancer through smell.

Combination treatment produces a complete response in mice with epithelial cancer.

Combination therapy targets tumors in epithelial cancer.

Toxin produced by cigarette smoke accelerates the growth of tumors.

Osimertinib (Tagrisso) approved for metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer.

Tyrosine kinase inhibitor improves survival in patients with rare lung cancer.

Ambitious project marks new era for pancreatic cancer patients, investigators say.

Overexpression of protein reveals why breast cancer spreads quickly.

Breast cancer cells may use reelin protein to evade the immune system.

Hodgkin lymphoma cancer survivors are 2.4 times more likely to develop a second type of cancer.

Scientists identify specific genes that cooperate with a well-known tumor suppressor gene.

Genes can interact with a tumor suppressor gene to prevent the development of breast, prostate, and skin cancer.

Study identifies 2 immune system molecules that may play a key role in drug-resistance.

The cytokines interleukin 1 beta (IL1β) and tumor necrosis factor alpha (TNFα) help the spread of drug-resistant cancer.

Baby Boomer age group testing levels for hepatitis C virus remained very low.

Study identifies potential Achilles heel of kinase-driven cancers.

Majority of patients were free from local recurrence after 1 year of reirradiation with an advanced form of proton therapy.

Top news of the day from across the health care landscape.

More than 3000 patients with breast cancer have received radiation with the Xoft System.

Treatment with endostatin slowed the proliferation of resistant prostate cancer cells.

Epalrestat could prevent metastasis in patients with basal-like triple-negative breast cancer.

High consumption of isoflavones reduced all-cause mortality in patients with breast cancer by 21%.

Repurposed drugs may provide new therapies for cancer.

Isoflavone supplements may influence outcomes among patients with breast cancer.

Most models were cancer-free within 6 weeks of treatment with selenomab-drug conjugates.

Next-generation antibody treatments effectively deliver cytotoxic drugs to tumors.